TCIM
ARGS

TIAA CREF Investment Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

TIAA CREF Investment Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,233
Closed -$219K – 3142
2016
Q4 		$219K Buy
2,233
+298
+15% +$27.9K ﹤0.01% 3031
2016
Q3 		$192 Hold
1,935
– – ﹤0.01% 3056
2016
Q2 		$237K Buy
+1,935
New +$258K ﹤0.01% 3073

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

TIAA CREF Investment Management's ARGS Position: Q1 2017 in Review

TIAA CREF Investment Management sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 2,233 shares — an estimated $219K sold.

TIAA CREF Investment Management first reported a position in ARGS in Q2 2016 and held it in 3 quarters. The position peaked at $237K in Q2 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

  • TIAA CREF Investment Management reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 2,233 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $219K.
  • TIAA CREF Investment Management first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • TIAA CREF Investment Management's Argos Therapeutics, Inc. position peaked at $237K in Q2 2016.
  • 43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on TIAA CREF Investment Management's 13F filing for Q1 2017, filed 11 May 2017.